On Monday, Shares of Hologic, Inc. (NASDAQ:HOLX), lost - 0.18% to $38.34.
Hologic, declared that the Company plans to release its financial results for the third quarter of fiscal 2015 on Wednesday, July 29, 2015, after the market closes. In conjunction with the release, administration will host a conference call that day at 4:30 p.m. Eastern Time.
Interested participants may listen to the call by dialing 877-723-9509 (in the United States) or 719-325-4804 (for international callers) and referencing access code 3002395. Participants should dial in 5-10 minutes before the call starts. A replay will be accessible about two hours after the call ends through Friday, August 28, 2015. The replay numbers are 888-203-1112 (U.S.) or 719-457-0820 (international), access code 3002395.
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States and internationally.
Shares of 500.com Ltd (NYSE:WBAI), declined -9.80% to $21.45, during its last trading session.
500.com Ltd, declared that it has reached a definitive purchase agreement with Tsinghua Unigroup International Co., Ltd. (“Tsinghua Unigroup”), a partner of Tsinghua Unigroup Co., Ltd, for the issuance and sale of newly issued ordinary shares of the Company.
Following the purchase agreement, Tsinghua Unigroup International Co., Ltd. will purchase 63,500,500 newly issued Class A ordinary shares of the Company for a total purchase price of about US$123.8 million in cash. The per share purchase price of US$1.95 (corresponding to US$19.5 per American Depository Receipts) represents a 1.4% discount of the average closing trading price of the Company’s ordinary shares for the 30 trading days ended June 8, 2015, or a 17.9% discount of the closing trading price of the Company’s ordinary shares on June 8, 2015, the day preceding to the date of the purchase agreement.
500.com Limited provides online sports lottery services in the Peoples Republic of China. It operates as an aggregator and processor of lottery purchase orders from its registered user accounts.
Finally, Seattle Genetics, Inc. (NASDAQ:SGEN), ended its last trade with -0.31% loss, and closed at $47.50.
Seattle Genetics, declared several ADCETRIS (brentuximab vedotin) data presentations at the 13th International Conference on Malignant Lymphoma (ICML) being held June 17 to 19, 2015, in Lugano, Switzerland. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL), systemic anaplastic large cell lymphoma (sALCL) and several other types of non-Hodgkin lymphoma (NHL). Seven oral presentations and one poster at ICML demonstrate the breadth of the clinical development program for ADCETRIS. Data comprise an additional analysis of the phase 3 AETHERA clinical trial showing that up to 16 cycles (about one year) of ADCETRIS consolidation therapy following autologous stem cell transplant (ASCT) significantly extended progression-free survival (PFS) as compared to placebo for those patients with primary-refractory HL. In addition, data from several corporate and investigator-sponsored trials with ADCETRIS showed activity in a variety of HL and NHL treatment settings. ADCETRIS is presently approved by the U.S. Food and Drug Administration (FDA) for relapsed HL and sALCL and was granted conditional marketing authorization by the European Commission for relapsed or refractory HL and sALCL.
Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
